Table 3.

Final data from the European (EU) trial, and interim and final data from the North American (NA) trial evaluating the effects of betaseron versus placebo on Expanded Disability Status Scale (EDSS) progression in patients with secondary-progressive multiple sclerosis

	Betaseron in secondary progressive MS patients
	Berlex North America (NA) Trial: February 1996–February 2000
	Number and percent with confirmed EDSS progression
	October 1998 EU Trial		October 1998NA Trial		February 2000NA Trial
	Bertaseron	Placebo	Betaseron	Placebo	Betaseron	Placebo
No. of patients	360	358	631	308	631	308
EDSS progression
Number	148	178	119	57	227	106
Percent	38.9	49.7	18.9	18.5	36.0	34.4
	OR=0.64, 2p=0.005		OR=1.03, 2p=0.90		OR=1.07, 2p=0.64